Article Details
Retrieved on: 2022-06-12 13:32:43
Tags for this article:
Click the tags to see associated articles and topics
Excerpt
In an earlier trial, efti was able to double the response rate of Keytruda in 1st line NSCLC and 2nd line HNSCC (TACTI-002 trial). That is, in a ...
Article found on: seekingalpha.com
This article is found inside other Hiswai user's workspaces. To start your own collection, sign up for free.
Sign UpAlready have an account? Log in here